EFCAB13

Across TCGA pan-cancer cohorts, EFCAB13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EFCAB13 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EFCAB13 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EFCAB13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, PRAD, and SARC are the cancer types where EFCAB13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.975	0.826	.007	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
COAD	DFS	Median	II,III,IV	1.000	0.471	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EFCAB13–UCEC (DFS)

Open the UCEC breakdown →